Efficacy and Safety of Tocilizumab for TAO
TocilizumabThyroid Associated OphthalmopathyThis study aims to evaluate the efficacy and safety of tocilizumab treating Thyroid Associated Ophthalmopathy.
A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001,...
Thyroid Eye DiseaseA randomized, double-masked, placebo-controlled safety, tolerability and efficacy study of VRDN-001 in participants with chronic thyroid eye disease (TED)
Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
Thyroid Eye DiseasePhase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
Thyroid Eye DiseaseTo evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
Anti-VEGF Therapy for Acute Thyroid Eye Disease
Thyroid Eye DiseaseThe primary objective of this clinical trial is to assess the safety and tolerability of sub-tenon aflibercept in combination with either saline or hyaluronidase (HA) in patients with acute Thyroid Eye Disease (TED) as assessed by the incidence and severity of adverse events from baseline to day 45. Participants will undergo clinical examinations and receive three injections of aflibercept with saline, aflibercept with hyaluronidase, or hyaluronidase.
Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO
Thyroid Associated OphthalmopathyThe purpose of this study is to determine whether periorbital injection of glucocorticoid is effective and necessary in the treatment of mild TAO.
A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid...
Thyroid Eye DiseaseThe investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease (TED). This clinical trial will evaluate the safety, tolerability and pharmacokinetics (the concentration of drug in the blood over time) of VRDN-001 in healthy volunteers and in patients with TED. Study participants with TED will also be evaluated over time for changes in their signs and symptoms of TED compared to their baseline measurements.
Hydroxychloroquine in Mild Graves' Orbitopathy
Graves OphthalmopathyThis study is aimed to investigate the effect of hydroxychloroquine in patients with mild Graves' orbitopathy (GO).
Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery.
Thyroid Associated OphthalmopathySurgical Procedure1 moreThis is a multicentric, randomized, single-blinded clinical trial to evaluate the efficacy and safety of 3D printing for the planification and simulation of orbital decompression surgery for thyroid-associated orbitopathy.
Tocilizumab in Active Moderate-severe Graves' Orbitopathy
Graves OphthalmopathyTo treat patientis with active moderate-severe GO with the anti-IL6 receptor monoclonal antibody tocilizubam with the purpose of assesing the efficacy of therapy on active GO and on the proportion of patiens with inactivation and reactivation of disease (Primary Objective) Effect of therapy on disease progression, improvement of QoL, the degree of residual disease after the inflammatory phase and safety of treatment (Secondary Objective)